GBM AGILE: Global Adaptive Trial Master Protocol: an International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM

• Age ≥ 18 years.

• Histologically confirmed Grade IV GBM, inclusive of gliosarcoma (WHO criteria; IDH wild-type by immunohistochemistry \[IHC\] or sequencing for IDH) established following either a surgical resection or biopsy. An MRI scan with the required imaging sequences performed within 21 days prior to randomization preferably. The post-operative MRI scan performed within 96 hours of surgery or the MRI scan performed for radiation therapy planning may serve as the MRI scan performed during screening if all required imaging sequences were obtained.

• Karnofsky performance status ≥ 60% performed within a 14-day window prior to randomization.

• Availability of tumor tissue representative of GBM from definitive surgery or biopsy.

• Age ≥ 18 years.

• Histologically confirmed Grade IV GBM, inclusive of gliosarcoma (WHO criteria; IDH wild-type by immunohistochemistry \[IHC\] or sequencing for IDH) at first or second recurrence after initial standard, control or experimental therapy that includes at a minimum radiation therapy (RT).

• Evidence of recurrent disease demonstrated by disease progression using slightly modified Response Assessment in Neuro-Oncology (RANO) criteria.

• Two scans to confirm progression are required: at least 1 scan at the time of progression and 1 scan prior to the time of progression.

• Karnofsky performance status ≥ 70% performed within a 14-day window prior to randomization.

• Availability of tumor tissue representative of GBM from initial definitive surgery and/or, recurrent surgery, if performed.